GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ADC Therapeutics SA (NYSE:ADCT) » Definitions » Pretax Margin %

ADCT (ADC Therapeutics) Pretax Margin % : -166.88% (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is ADC Therapeutics Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. ADC Therapeutics's Pre-Tax Income for the three months ended in Mar. 2025 was $-38.44 Mil. ADC Therapeutics's Revenue for the three months ended in Mar. 2025 was $23.03 Mil. Therefore, ADC Therapeutics's pretax margin for the quarter that ended in Mar. 2025 was -166.88%.

The historical rank and industry rank for ADC Therapeutics's Pretax Margin % or its related term are showing as below:

ADCT' s Pretax Margin % Range Over the Past 10 Years
Min: -10778.25   Med: -741.53   Max: -69.94
Current: -196.28


ADCT's Pretax Margin % is ranked worse than
57.45% of 980 companies
in the Biotechnology industry
Industry Median: -110.75 vs ADCT: -196.28

ADC Therapeutics Pretax Margin % Historical Data

The historical data trend for ADC Therapeutics's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ADC Therapeutics Pretax Margin % Chart

ADC Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only - -741.53 -69.94 -280.94 -220.42

ADC Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -253.45 -205.13 -236.24 -183.61 -166.88

Competitive Comparison of ADC Therapeutics's Pretax Margin %

For the Biotechnology subindustry, ADC Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ADC Therapeutics's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ADC Therapeutics's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where ADC Therapeutics's Pretax Margin % falls into.


;
;

ADC Therapeutics Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

ADC Therapeutics's Pretax Margin for the fiscal year that ended in Dec. 2024 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-156.136/70.837
=-220.42 %

ADC Therapeutics's Pretax Margin for the quarter that ended in Mar. 2025 is calculated as

Pretax Margin=Pre-Tax Income (Q: Mar. 2025 )/Revenue (Q: Mar. 2025 )
=-38.437/23.033
=-166.88 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ADC Therapeutics  (NYSE:ADCT) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


ADC Therapeutics Pretax Margin % Related Terms

Thank you for viewing the detailed overview of ADC Therapeutics's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


ADC Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
Route de la Corniche 3B, Biopole, Epalinges, CHE, 1066
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).